Eliglustat

Brand names: Cerdelga · Active ingredient: Eliglustat

In short: CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test . Limitations of Use: Patients who are CYP2D6 ultra-rapid

Forms & strengthsCapsules: 84 mg of eliglustat is in a capsule with a pearl blue-green opaque cap and pearl white opaque body imprinted with "GZ02" in black.
LabelGenzyme Corporation
Label updatedMar 11, 2024

What is Eliglustat used for?

CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test .

Limitations of Use:

Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect .

A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers) .

Eliglustat dosage

Select patients with Gaucher disease type 1 based on their CYP2D6 metabolizer status. It is recommended patient genotypes be established using an FDA-cleared test for determining CYP2D6 genotype .

The recommended dosage of CERDELGA in adults is based on the patient's CYP2D6 metabolizer status.

CYP2D6 Metabolizer Status | CERDELGA Dosage

EMs | 84 mg twice daily

IMs

PMs | 84 mg once daily

Reduce dosage frequency of CERDELGA 84 mg to once daily in CYP2D6 EMs and IMs with or without hepatic impairment taking CYP2D6 or CYP3A inhibitors, as shown in Table 2 [see Warnings and Precautions (5.1), Drug Interactions (7.1), Use in Specific Populations (8.7)].

CYP2D6 Metabolizer Status | Hepatic Impairment Status | Concomitant CYP Inhibitor

EMs | Without Hepatic Impairment | Taking a strong or moderate CYP2D6 inhibitor

Taking a strong or moderate CYP3A inhibitor

Mild (Child-Pugh Class A) Hepatic Impairment | Taking a weak CYP2D6 inhibitor

Taking a strong, moderate, or weak CYP3A inhibitor

IMs | Without Hepatic Impairment | Taking a strong or moderate CYP2D6 inhibitor

Swallow capsules whole, preferably with water, and do not crush, dissolve, or open the capsules.

CERDELGA can be taken with or without food.

Avoid the consumption of grapefruit or grapefruit juice (strong CYP3A inhibitors) with CERDELGA .

If a dose of CERDELGA is missed, take the prescribed dose at the next scheduled time; do not double the next dose.

For patients currently treated with imiglucerase, velaglucerase alfa, or taliglucerase alfa, CERDELGA may be administered 24 hours after the last dose of the previous enzyme replacement therapy (ERT).

How to take Eliglustat — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Drug Interactions

Advise patients to discuss all the medications they are taking, including any herbal supplements or vitamins with their healthcare provider .

ECG Changes and Potential for Cardiac Arrhythmias

Advise patients to inform their healthcare provider of the following: history of congestive heart failure; recent acute myocardial infarction; bradycardia; heart block; ventricular arrhythmia; and long QT syndrome .

Advise patients to inform their healthcare provider if they develop new symptoms such as palpitations, fainting, and dizziness.

Administration Instructions

Advise patients:

Swallow capsules whole, preferably with water, and do not crush, dissolve, or open the capsules.

CERDELGA can be taken with or without food.

If a dose of CERDELGA is missed, take the prescribed dose at the next scheduled time; do not double the next dose.

Avoid consumption of grapefruit or its juice.

For patients currently treated with imiglucerase, velaglucerase alfa, or taliglucerase alfa, CERDELGA may be administered 24 hours after the last dose of the previous enzyme replacement therapy (ERT).

Warnings & precautions

Do not take this medicine if: CERDELGA is contraindicated in the following patients based on CYP2D6 metabolizer status due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals.

EMs

Taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor

Moderate or severe hepatic impairment

Mild hepatic impairment and taking a strong or moderate CYP2D6 inhibitor

IMs

Taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor

Taking a strong CYP3A inhibitor

Any degree of hepatic impairment

PMs

Taking a strong CYP3A inhibitor

Any degree of hepatic impairment

CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations and may increase the risk of cardiac arrhythmias.

Use of CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients taking CYP2D6 or CYP3A inhibitors, depending on CYP2D6 metabolizer status, type of inhibitor, or degree of hepatic impairment .

Use of CERDELGA in patients with pre-existing cardiac conditions has not been studied during clinical trials. Avoid use of CERDELGA in patients with:

pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia)

long QT syndrome

in combination with Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications

Eliglustat side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions to CERDELGA (occurring in ≥10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.

The adverse reaction profile of CERDELGA is based on two controlled studies, Trials 1 and 2 . Table 3 presents the profile from the 9-month double-blind, randomized, placebo-controlled trial of 40 treatment-naive patients (Trial 1). Patients were between the ages of 16 and 63 on the date of the first dose of study drug, and included 20 males and 20 females.

CERDELGA(N=20) | Placebo(N=20)

Adverse Reaction | Patientsn (%) | Patientsn (%)

Arthralgia | 9 (45) | 2 (10)

Headache | 8 (40) | 6 (30)

Migraine | 2 (10) | 0 (0)

Flatulence | 2 (10) | 1 (5)

Nausea | 2 (10) | 1 (5)

Oropharyngeal pain | 2 (10) | 1 (5)

Table 4 presents the profile from the 12-month open-label, randomized, imiglucerase-controlled trial of 159 treated patients switching from enzyme replacement therapy (ERT) (Trial 2). Patients were between the ages of 18 and 69 on the date of the first dose of CERDELGA, and included 87 females and 72 males. …

Drug interactions

Coadministration of CERDELGA with:

CYP2D6 or CYP3A inhibitors may increase eliglustat concentrations which may increase the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac interval .

strong CYP3A inducers decrease eliglustat concentrations which may reduce CERDELGA efficacy .

See Table 5 for prevention and management of interactions with drugs affecting CERDELGA. Use of CERDELGA is contraindicated, to be avoided, or may require dosage adjustment depending on the concomitant drug and CYP2D6 metabolizer status .

Concomitant Drug(s) | CYP2D6 Metabolizer Status

EMs | IMs | PMs

CYP2D6 Inhibitor

Strong | Reduce frequency of CERDELGA 84 mg to once daily | Continue CERDELGA 84 mg once dailyNo effect of CYP2D6 inhibitor due to little or no CYP2D6 activity in CYP2D6 PMs. …

About this medicine

CERDELGA (eliglustat) capsules contain eliglustat tartrate, which is a small molecule inhibitor of glucosylceramide synthase that resembles the ceramide substrate for the enzyme, with the chemical name N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide (2R,3R)-2,3-dihydroxysuccinate. Its molecular weight is 479.59, and the empirical formula is C23H36N2O4+½(C4H6O6) with the following chemical structure:

Each capsule of CERDELGA for oral use contains 84 mg of eliglustat (equivalent to 100 mg of eliglustat tartrate). The inactive ingredients are candurin silver fine, FD&C blue 2, gelatin, glyceryl behenate, hypromellose, lactose monohydrate, microcrystalline cellulose, and yellow iron oxide.

How it works: Gaucher disease is caused by a deficiency of the lysosomal enzyme acid β-glucosidase. Acid β-glucosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 819f828a-b888-4e46-83fc-94d774a28a83. Read the full official label on DailyMed.